New drug aims to boost platelets in breast cancer patients on chemo
NCT ID NCT07162519
First seen Jun 25, 2026 · Last updated Jun 25, 2026
Summary
This study tests a drug called romiplostim N01 to treat low platelet counts caused by chemotherapy in breast cancer patients. Researchers will enroll 68 participants and give them weekly injections for up to 4 weeks. The main goal is to see how many patients' platelet levels return to a safe range within two weeks.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
romiplostim N01
What this could lead to
If it works, this could offer a way to manage chemotherapy-induced low platelets in breast cancer patients, helping them continue treatment.
What could go wrong
This is a small, early-phase study with no control group. It may not work for everyone, and side effects or lack of response are possible.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.